Search PubMed⌕ Search

PubMed · 3158262

The hypercoagulable states.

Abstract

Patients are considered to have hypercoagulable states if they have laboratory abnormalities or clinical conditions that are associated with an increased risk of thrombosis (prethrombotic states) or if they have recurrent thrombosis without recognizable predisposing factors (thrombosis-prone). The number of specific primary hypercoagulable states that are recognized is growing. These disorders are generally inherited abnormalities of coagulation in which a physiologic anticoagulant mechanism is defective: for example, antithrombin III deficiency, protein C and protein S deficiency, abnormalities of the fibrinolytic system, and dysfibrinogenemias. Secondary hypercoagulable states are generally acquired disorders in patients with underlying systemic diseases or clinical conditions known to be associated with an increased risk of thrombosis: for example, malignancy, pregnancy, use of oral contraceptives, myeloproliferative disorders, hyperlipidemia, diabetes mellitus, and abnormalities of blood vessels and rheology. The complex pathophysiologic features of these secondary hypercoagulable states are discussed, and a framework is provided for the laboratory investigation and systematic clinical approach to the patient.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A I Schafer. 1985. The hypercoagulable states.. https://doi.org/10.7326/0003-4819-102-6-814

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Olav Egeberg--hereditary antithrombin deficiency and thrombophilia].

In 1965 Olav Egeberg (1916-77) presented the first report that linked a defined, hereditary defect in the control of blood coagulation to thrombotic disease. Having examined a family in which several members had sustained venous thrombosis, he demonstrated that antithrombin activity was clearly subnormal in the affected members. Heparin cofactor activity was also subnormal in these persons. This supported the hypothesis that the two activities might reside in a single protein. The condition was inherited as an autosomal dominant trait. Egeberg's publication initiated thrombophilia as a rewarding research area, and also as an important clinical discipline.

Antithrombin III Deficiency↗

Molecular bases of antithrombin deficiency in French families: identification of seven novel mutations in the antithrombin gene.

We have investigated the molecular bases of familial antithrombin deficiency in eight French families. Eight mutations in the antithrombin coding exons were identified, seven of which were novel mutations. In all cases, individuals were heterozygous for the mutation. We found two small frameshift deletions in exon 3a, leading to type I deficiency. Five missense mutations in exons 3b or 5 also caused type I deficiency and their potential consequences on the antithrombin three-dimensional structure were analysed. The last mutation in exon 4 was associated with a type II 'reactive site' deficiency: a dysfunctional antithrombin that is affected in its interaction with thrombin was present in circulation.

Antithrombin III Deficiency↗